The invention relates to a compound (I) wherein R is aheterocyclyl radical； R1 and R2 are independently H or alkyl；R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl,arylalkyl, heterocyclyl or heterocyclylalkyl； R4 and R5 areindependently H or alkyl； q is a number selected from 0 and 1；and the salts, solvates, prodrugs or stereoisomers thereofhaving inhibitory activity for UBC13-UEV interactions andwhich can be used in the production of pharmaceuticalcompositions intended for antitumor therapy or the treatmentand/or prophylaxis of diseases associated to metabolicpathways involving the UBC13 enzyme, metabolic pathwaysinvolving transcriptional factor NF-.kappa.B, or pathways involvingPCNA or RAD6.R- (CR1R2) q-CO-N (R3) -C (R4R5) -CO-NH2(I)
